Drug Profile
Research programme: immune modulation therapies - Aus Bio
Alternative Names: MD 2001; PC 2000Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Aus Bio Limited
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Hepatitis B; Hepatitis C; Respiration disorders; Ulcerative colitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Crohn's-disease in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in Australia